Status:
COMPLETED
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Meningitis, Meningococcal
Eligibility:
All Genders
18-25 years
Phase:
PHASE1
Brief Summary
To determine the safety \& immunogenicity of a potential vaccine against meningococcal B disease
Eligibility Criteria
Inclusion
- Healthy 18-25 year olds
Exclusion
- Prior history of vaccination with any meningococcal vaccine
- Prior history of any invasive meningococcal disease
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00297687
Start Date
March 1 2006
End Date
March 1 2007
Last Update
December 5 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Herson, Queensland, Australia, 4006
2
North Adealaide, South Australia, Australia, 5006
3
Perth, Western Australia, Australia, 6840